<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111034</article-id><article-id pub-id-type="publisher-id">ACM-39985</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_75301184.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  狼疮性肾炎患者肠道菌群变化及代谢物硫酸吲哚酚分析
  Analysis of Intestinal Flora and Indoxyl Sulfate in the Patients with Lupus Nephritis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苏</surname><given-names>晗</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邢</surname><given-names>倩</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属青岛市市立医院，风湿免疫科，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学附属青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>235</fpage><lpage>242</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析狼疮性肾炎(Lupus nephritis, LN)患者与健康人群肠道菌群的结构及代谢产物差异，探讨肠道菌群在LN发病中的作用。方法：选取系统性红斑狼疮患者51例，分为狼疮性肾炎组(LN组) 27例和狼疮非肾炎组(N-LN组) 24例，另选取53例健康志愿者作为健康对照组(H组)。基于Illumina MiSeq平台分别对SLE患者和健康对照组的粪便样本进行Alpha多样性分析、Beta多样性分析以及属水平上的菌群差异性分析，采用ELISA双抗体夹心法测定SLE患者和健康对照组血清硫酸吲哚酚(IS)浓度，对LN患者的24h尿蛋白定量与其血清IS浓度进行Pearson相关性分析，采用受试者工作曲线(ROC曲线)，根据最佳敏感性和特异性确定IS诊断界点。结果：LN组较健康对照组血IS浓度和肠杆菌含量均显著升高，差异有统计学意义(P &lt; 0.05)。在LN患者中，24 h尿蛋白定量与血清IS浓度呈正相关(r = 0.86, P &lt; 0.01)。结论：狼疮性肾炎患者存在肠道菌群失调，肠杆菌含量明显增加，相关代谢产物血清IS异常，可能参与LN发病。
    Objective: To analyze the structure and metabolites of intestinal flora in patients with lupus nephritis and healthy controls, and to explore the role of intestinal flora in the pathogenesis of LN. Methods: 51 patients with systemic lupus erythematosus were divided into the lupus nephritis group (group LN, n = 27) and the lupus non-glomerulonephritis group (group N-LN, n = 24), and 53 healthy volunteers were selected as the healthy control group (group H). Based on the IlluminaMiSeq platform, the fecal samples of SLE patients and healthy controls were analyzed by Alpha diversity analysis, Beta diversity analysis and flora difference analysis at genus level. The blood Indoxyl sulfate (IS) concentration in SLE patients and healthy controls was determined by ELISA double antibody sandwich method. The correlation between the 24 h urinary protein quantification and the blood IS concentration in LN patients was examined by the Pearson correlation test. The best cutoffs for the blood IS concentration in predicting a 24 h urinary protein quantification were determined with the receiver operating characteristic curve (ROC). Results: The blood IS concentration and the content of fecal Faecalibacterium in group LN were significantly higher than those in the healthy control group (P &lt; 0.05). In patients with LN, the 24 h urinary protein quantification was positively correlated with the blood IS concentration (r = 0.86, P &lt; 0.01). Conclusion: The patients with lupus nephritis have intestinal flora imbalance, the content of fecal Faecalibacterium is significantly increased, and the blood IS concentration is abnormal, which may be involved in the pathogenesis of LN. 
  
 
</p></abstract><kwd-group><kwd>狼疮性肾炎，肠道菌群，24 h尿蛋白定量，硫酸吲哚酚, Lupus Nephritis</kwd><kwd> Intestinal Flora</kwd><kwd> 24 h Urinary Protein Quantification</kwd><kwd> Indoxyl Sulfate</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析狼疮性肾炎(Lupus nephritis, LN)患者与健康人群肠道菌群的结构及代谢产物差异，探讨肠道菌群在LN发病中的作用。方法：选取系统性红斑狼疮患者51例，分为狼疮性肾炎组(LN组) 27例和狼疮非肾炎组(N-LN组) 24例，另选取53例健康志愿者作为健康对照组(H组)。基于Illumina MiSeq平台分别对SLE患者和健康对照组的粪便样本进行Alpha多样性分析、Beta多样性分析以及属水平上的菌群差异性分析，采用ELISA双抗体夹心法测定SLE患者和健康对照组血清硫酸吲哚酚(IS)浓度，对LN患者的24h尿蛋白定量与其血清IS浓度进行Pearson相关性分析，采用受试者工作曲线(ROC曲线)，根据最佳敏感性和特异性确定IS诊断界点。结果：LN组较健康对照组血IS浓度和肠杆菌含量均显著升高，差异有统计学意义(P &lt; 0.05)。在LN患者中，24 h尿蛋白定量与血清IS浓度呈正相关(r = 0.86, P &lt; 0.01)。结论：狼疮性肾炎患者存在肠道菌群失调，肠杆菌含量明显增加，相关代谢产物血清IS异常，可能参与LN发病。</p></sec><sec id="s2"><title>关键词</title><p>狼疮性肾炎，肠道菌群，24 h尿蛋白定量，硫酸吲哚酚</p></sec><sec id="s3"><title>Analysis of Intestinal Flora and Indoxyl Sulfate in the Patients with Lupus Nephritis<sup> </sup></title><p>Han Su<sup>1</sup>, Qian Xing<sup>2*</sup></p><p><sup>1</sup>Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Rheumatic Immunity, Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/34-1571897x5_hanspub.png" /></p><p>Received: Dec. 25<sup>th</sup>, 2020; accepted: Jan. 19<sup>th</sup>, 2021; published: Jan. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/34-1571897x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the structure and metabolites of intestinal flora in patients with lupus nephritis and healthy controls, and to explore the role of intestinal flora in the pathogenesis of LN. Methods: 51 patients with systemic lupus erythematosus were divided into the lupus nephritis group (group LN, n = 27) and the lupus non-glomerulonephritis group (group N-LN, n = 24), and 53 healthy volunteers were selected as the healthy control group (group H). Based on the IlluminaMiSeq platform, the fecal samples of SLE patients and healthy controls were analyzed by Alpha diversity analysis, Beta diversity analysis and flora difference analysis at genus level. The blood Indoxyl sulfate (IS) concentration in SLE patients and healthy controls was determined by ELISA double antibody sandwich method. The correlation between the 24 h urinary protein quantification and the blood IS concentration in LN patients was examined by the Pearson correlation test. The best cutoffs for the blood IS concentration in predicting a 24 h urinary protein quantification were determined with the receiver operating characteristic curve (ROC). Results: The blood IS concentration and the content of fecal Faecalibacterium in group LN were significantly higher than those in the healthy control group (P &lt; 0.05). In patients with LN, the 24 h urinary protein quantification was positively correlated with the blood IS concentration (r = 0.86, P &lt; 0.01). Conclusion: The patients with lupus nephritis have intestinal flora imbalance, the content of fecal Faecalibacterium is significantly increased, and the blood IS concentration is abnormal, which may be involved in the pathogenesis of LN.</p><p>Keywords:Lupus Nephritis, Intestinal Flora, 24 h Urinary Protein Quantification, Indoxyl Sulfate</p><disp-formula id="hanspub.39985-formula23"><graphic xlink:href="//html.hanspub.org/file/34-1571897x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/34-1571897x8_hanspub.png" /> <img src="//html.hanspub.org/file/34-1571897x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种以大量自身抗体产生为特征的全身性自身免疫性疾病，可累及肾脏、心脏、神经系统等多个脏器，约50%~70%的SLE患者合并肾脏损害，SLE患者早期肾脏受累通常预后不良 [<xref ref-type="bibr" rid="hanspub.39985-ref1">1</xref>]。狼疮性肾炎(lupus nephritis, LN)患者肾脏受累的表型形式复杂多样，如蛋白尿、管型尿、血尿及不同程度的肾功能损害，其中以蛋白尿最为常见。临床上通常以24 h尿蛋白定量评估LN患者病情严重程度。SLE的发病与遗传、环境密切相关，目前病因不明，但近年来发现肠道菌群的紊乱可能参与了SLE的发病 [<xref ref-type="bibr" rid="hanspub.39985-ref2">2</xref>]。肠道是人体最大的免疫器官，正常情况下肠道菌群按照一定的比例相互制约调节肠道的稳态和免疫状态 [<xref ref-type="bibr" rid="hanspub.39985-ref3">3</xref>]。当肠道菌群比例失调，将会破坏肠道屏障的稳态从而导致自身免疫性疾病的发生 [<xref ref-type="bibr" rid="hanspub.39985-ref4">4</xref>]，其致病机制可能与肠道代谢物密切相关。</p><p>血清硫酸吲哚酚(Indoxyl sulfate, IS)是一种由肠杆菌(Faecalibacterium)等菌群代谢产生的一种蛋白结合类的肾毒性物质，其可以通过氧化应激及相关炎症反应损害肾脏血管内皮，从而损伤肾脏 [<xref ref-type="bibr" rid="hanspub.39985-ref5">5</xref>]。IS对肾脏等靶器官的损害是近年来研究的热点之一。但LN患者中尿蛋白与血清IS浓度是否存在相关关系尚不明确。本文旨在通过研究LN患者与健康人群肠道菌群的结构差异，分析24 h尿蛋白定量与血清IS浓度之间的关系，进一步评估血清IS浓度与LN患者肾脏损害之间的关联性，从而为寻求LN新的治疗靶点提供理论依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>收集2018年9月至2020年10月在青岛市市立医院风湿免疫科门诊及病房治疗的已确诊及新发SLE患者，作为SLE组，共计51例。所有SLE患者均符合美国风湿病学会(American Rheumatism Association criteria, ARA)在1997年所修订的SLE分类标准 [<xref ref-type="bibr" rid="hanspub.39985-ref6">6</xref>]，LN患者同时具备上述SLE分类标准并具有以下一项以上表现：1) 蛋白尿：&gt;0.5 g/24h；2) 管型：红细胞、血红蛋白、颗粒管型或混合管型；3) 肾活检：证实为狼疮性肾炎，病理改变符合国际肾脏病学会/肾脏病理学会(ISN/RPS分类标准)。入选24 h尿蛋白定量 &gt; 0.5 g的LN患者作为狼疮性肾炎组(LN组，27例)，男8例，女19例，平均年龄36.11 &#177; 10.99岁；明确无狼疮性肾炎的SLE患者作为狼疮无肾炎组(N-LN组，24例)，男6例，女18例，平均年龄37.58 &#177; 9.84岁。另选取健康志愿者作为对照组(H组，53例)，男18例，女35例，平均年龄37.96 &#177; 10.73岁。健康对照组与SLE组在性别、年龄上差异无统计学意义(P &gt; 0.05)。</p><p>本研究的各个程序均符合医院伦理委员会所制定的伦理学标准，所有入组对象均签署知情同意书。</p><sec id="s6_1_1"><title>2.1.1. 纳入标准</title><p>1) 符合ARA在1997年SLE分类诊断标准；2) 年龄18~60周岁；3) 体质量指数在正常范围之内，无超重或肥胖；4) 未重叠其他风湿性疾病如类风湿性关节炎、干燥综合征等；5) 在采样前，受试者至少8周未接受抗生素或益生菌治疗；6) 无特殊饮食习惯。</p></sec><sec id="s6_1_2"><title>2.1.2. 排除标准</title><p>1) 正在进行或既往进行过肾脏透析的患者；2) 肾脏移植患者；3) 肌酐清除率 &lt; 15 ml/min；4) 患有高血压、糖尿病，精神疾病，胃肠炎及其他炎症性疾病和传染病等；5) 入院前服用过糖皮质激素或免疫抑制剂药物；6) 失访者。</p></sec></sec><sec id="s6_2"><title>2.2. 方法</title><sec id="s6_2_1"><title>2.2.1. 尿液的收集与检测</title><p>嘱SLE患者和健康对照组于第一天早7点排空膀胱后，收集第一天早7点到第二天早7点的24小时尿量于干燥洁净的容器中，充分混匀后用专用尿液收集器取5 ml尿液送于检验科测定其蛋白质浓度，再与24小时尿液总量相乘，即得到24小时尿蛋白总量。</p></sec><sec id="s6_2_2"><title>2.2.2. 粪便的收集与菌群的测定</title><p>采用专用粪便标本采集管，分别收集SLE组和健康对照组的粪便样本，利用Illumina MiSeq平台对样本16S rRNA基因序列V3~V4高变区进行PCR扩增及测序，对SLE组和健康对照组进行Alpha多样性分析、Beta多样性分析，并在属水平上对SLE组与健康对照组粪便中肠杆菌的含量进行差异性分析。</p></sec><sec id="s6_2_3"><title>2.2.3. 酶联免疫法(ELISA)测定血硫酸吲哚酚</title><p>分别采取SLE组和健康对照组晨起静脉血2 ml，取上清液于EP管在−80℃冰箱中保存。检测采用双抗体夹心法，严格按说明书操作。</p></sec></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>采用SPSS20.0进行统计学分析，计量资料以均数&#177;标准差表示，用Pearson进行相关性分析。P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 狼疮性肾炎组与健康对照组肠道菌群存在差异</title><p>本研究基于OTU水平对SLE组和健康对照组在Illumna MiSeq平台进行肠道菌群Alpha多样性分析和Beta多样性分析，发现SLE组患者较健康对照组Alpha多样性、Beta多样性显著下降，其中LN组较健康对照组下降更为显著，差异有统计学意义(P &lt; 0.05)。在菌门水平上，SLE组粪便中厚壁菌门含量较健康对照组显著下降(P &lt; 0.05)，拟杆菌门显著上升(P &lt; 0.05)，厚壁菌门/拟杆菌门(F/B)比率显著下降(P &lt; 0.05)。在菌属水平上，LN组粪便中双歧杆菌、乳酸杆菌等含量较健康对照组下降(P &lt; 0.05)，而肠杆菌、瘤胃球菌属等含量较健康对照组上升(P &lt; 0.05)，见图1。其中LN组粪便中肠杆菌的含量较健康对照组显著上升(P &lt; 0.01)，见图2。</p><p>图1. 物种分布柱状图</p><p>图2. 肠杆菌含量差异柱状图，*: P &lt; 0.01</p></sec><sec id="s7_2"><title>3.2. 狼疮性肾炎组与健康对照组血清IS浓度存在差异</title><p>LN组血清IS浓度为(100.56 &#177; 18.57) pg/ml，狼疮无肾炎组血清IS浓度为(17.13 &#177; 3.25) pg/ml，健康对照组血清IS浓度为(11.06 &#177; 2.41) pg/ml。LN组血清IS浓度较狼疮无肾炎组、健康对照组均显著增加(P &lt; 0.001)。进一步对LN组的24 h尿蛋白定量与血清IS浓度进行相关性分析，发现LN组的24 h尿蛋白定量与其血清IS浓度之间呈正相关(r = 0.86, P &lt; 0.01)，即随着LN组24 h尿蛋白定量的增加，其血清中的IS浓度也随之升高，见图3。其相关性方程式为Y = 6.79 * X + 26.28。</p><p>图3. 相关性分析散点图</p></sec><sec id="s7_3"><title>3.3. 硫酸吲哚酚预测狼疮性肾炎患者的24 h尿蛋白定量水平</title><p>把IS作为诊断指标，将24 h尿蛋白定量是否大于0.5 g作为分组变量，绘制SLE组的ROC曲线，见图4。结果显示，血清IS曲线下面积AUC = 0.755，诊断有统计学意义(P = 0.002)。通过尤登指数(即敏感度 + 特异度-1)计算得出，血清IS的ROC曲线，其最佳界值出现在敏感度为0.778，特异度为0.625时，最佳诊断界值为74 pg/ml。即当血清IS浓度在74 pg/ml时，能较好的反映LN患者的24 h尿蛋白定量水平。</p><p>图4. 血清IS的ROC曲线</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>目前，国内外研究均证实SLE患者存在不同程度的肠道菌群失调 [<xref ref-type="bibr" rid="hanspub.39985-ref7">7</xref>]，其中最具特征性的为厚壁菌和拟杆菌比值(F/B)的降低 [<xref ref-type="bibr" rid="hanspub.39985-ref8">8</xref>]。有研究显示，SLE患者肠道菌群中链球菌和乳杆菌显著增多，而费氏杆菌显著减少 [<xref ref-type="bibr" rid="hanspub.39985-ref9">9</xref>]；另有研究显示SLE患者肠道菌群中乳酸杆菌显著降低，毛螺菌和瘤胃球菌显著增加 [<xref ref-type="bibr" rid="hanspub.39985-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.39985-ref11">11</xref>]。肠道菌群多样性下降 [<xref ref-type="bibr" rid="hanspub.39985-ref12">12</xref>]，肠道菌群及其代谢产物的紊乱 [<xref ref-type="bibr" rid="hanspub.39985-ref13">13</xref>] 可使全身免疫系统过度活跃，从而导致自身免疫病的发生发展。本研究发现，与健康对照组相比，SLE患者粪便双歧杆菌、乳酸杆菌等有益菌含量显著减少，而肠杆菌、瘤胃球菌属等菌群含量增多。其中，LN患者粪便菌群多样性较健康对照组显著下降，其肠杆菌含量较健康对照组显著增加，提示我们可能由于肠杆菌及其代谢产物含量的增加，并通过某种途径参与了自身免疫系统的调节而导致了LN的发病。</p><p>一直以来，LN的发病机制认为主要是在自身抗体的作用下，导致补体和免疫复合物沉积于肾小球，从而趋化了IL-17、IL-6、TNF γ等炎症因子造成肾脏的局部炎症反应 [<xref ref-type="bibr" rid="hanspub.39985-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.39985-ref15">15</xref>]。而新近研究表明，肾脏在无免疫复合物沉积的情况下仍可出现不同程度的损伤 [<xref ref-type="bibr" rid="hanspub.39985-ref16">16</xref>]，提示存在其他危害肾脏的因素。IS是一种分子量大小约251 Da的蛋白结合型尿毒症毒素 [<xref ref-type="bibr" rid="hanspub.39985-ref17">17</xref>]，是由肠杆菌等菌群产生的肠道代谢产物 [<xref ref-type="bibr" rid="hanspub.39985-ref18">18</xref>]。肠杆菌等通过对肠道中潴留的色氨酸进行分解代谢，产生吲哚后吸收入血，在肝脏中羟基化生成3-羟基吲哚，最终经硫酸化形成IS [<xref ref-type="bibr" rid="hanspub.39985-ref19">19</xref>]。血清IS浓度与肾功能呈负相关，在肾功能正常的情况下，血清IS主要通过肾小管分泌清除后随尿液排出；当肾功能受损时，经尿液排出的IS随之减少，从而造成了IS在体内的聚集，进一步加重了肾脏的损害 [<xref ref-type="bibr" rid="hanspub.39985-ref20">20</xref>]。近年来，认为IS与慢性肾脏病的发生发展密切相关。目前认为，血清IS不仅可以通过促进炎症因子如IL-6、IL-17的表达导致肾脏发生局部炎症反应，还可以对细胞内活性氧水平进行上调 [<xref ref-type="bibr" rid="hanspub.39985-ref5">5</xref>]，诱发血管舒缩反应的失衡，进而导致肾脏系统内皮发生损伤。LN作为一种危害性极大的肾脏疾病，常导致不同程度的肾脏损伤。</p><p>本研究发现，LN患者与健康人肠道菌群的结构和比例存在不同程度的差异，其肠道益生菌比例下降，而肠道有害菌比例上升，且肠道菌群多样性下降，LN患者肠道中产IS的大肠杆菌含量的增多，LN患者24 h尿蛋白定量与其血清IS浓度呈正相关，提示IS与LN的发病之间可能存在某种关联，推测IS与LN病情可能存在互为因果的关系。一方面由于LN患者肠道菌群的失调，使肠道中产IS的肠杆菌显著增加，增加了血清IS的含量；另一方面，由于LN患者本身存在的肾脏器质性改变导致血清IS排出受阻而蓄积，进一步加重了肾脏病情从而尿蛋白量增加。</p><p>近年来，对于肠道菌群及其代谢产物的研究越来越多，发现多种肠道菌及其代谢产物与肾脏疾病密切相关。有研究发现，三甲氧胺(TMAO)的增加与肾脏疾病的发生发展及预后相关 [<xref ref-type="bibr" rid="hanspub.39985-ref21">21</xref>]。TMAO是在肠道内经肠道菌代谢胆碱及卵磷脂生成的代谢产物，吸收入血后在肝脏单加氧酶的作用下进一步氧化生成TMAO，其含量被证实与拟杆菌目呈正相关 [<xref ref-type="bibr" rid="hanspub.39985-ref22">22</xref>]。目前口服益生菌制剂 [<xref ref-type="bibr" rid="hanspub.39985-ref23">23</xref>] 及进行粪便移植 [<xref ref-type="bibr" rid="hanspub.39985-ref24">24</xref>]，是主要的改善肠道菌群紊乱的方式，可以在一定程度上干预自身免疫性疾病的发病及病情严重程度。最新研究发现，维生素B3的代谢产物胡芦巴碱不仅可以抑制大肠杆菌、粪肠球菌等条件致病菌生长，还可以抑制TMAO的生成 [<xref ref-type="bibr" rid="hanspub.39985-ref25">25</xref>]。Wikoff等提出了肾毒性的肠道菌群代谢产物马尿酸和苯乙酸 [<xref ref-type="bibr" rid="hanspub.39985-ref26">26</xref>]；Jones在慢性肾脏病患者体内发现了可经由肠道微生物代谢产生的胍类化合物，部分具有肾毒性 [<xref ref-type="bibr" rid="hanspub.39985-ref27">27</xref>]；吲哚乙酸具有诱导肾小球硬化、肾间质纤维化的作用 [<xref ref-type="bibr" rid="hanspub.39985-ref28">28</xref>]；血中对甲酚硫酸盐含量的升高与慢性肾脏病患者的病死率相关联 [<xref ref-type="bibr" rid="hanspub.39985-ref29">29</xref>]。临床研究已经证实了肾脏病与IS之间的关联性，而LN作为肾脏病的一种，通过降低SLE患者血清中IS的浓度，可能成为将来预防及改善LN患者肾脏损害的一种新型治疗手段。目前，血清IS可以通过调节肠道菌群、口服吸附制剂、血液透析等方式清除 [<xref ref-type="bibr" rid="hanspub.39985-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.39985-ref31">31</xref>]。因此通过给予LN患者口服胡芦巴碱等物质抑制肠道中大肠杆菌等条件致病菌的生长，从而减少IS等肾毒性肠道菌群代谢产物的生成，可能会延缓LN患者肾脏病情的进展。</p></sec><sec id="s9"><title>5. 不足与展望</title><p>由于实验室条件限制，本实验对IS的浓度测定采用酶联免疫法进行，目前国内外对IS的测定多采用液相色谱–质谱分析法，其准确度更佳，但酶联免疫法检测IS浓度价格便宜、操作方便，临床中可用于初步评估。此外，本研究中LN患者的样本量不足，且饮食习惯存在地域差别，需要多地域更大的样本量来进行证实研究。因此，我们下阶段将优化实验方法及样本量，从不同的肠道菌群和代谢产物角度出发，通过改善肠道菌群结构从而抑制肾毒性肠道菌代谢产物，为延缓及防治肾脏疾病提供新的治疗思路。</p></sec><sec id="s10"><title>文章引用</title><p>苏 晗,邢 倩. 狼疮性肾炎患者肠道菌群变化及代谢物硫酸吲哚酚分析Analysis of Intestinal Flora and Indoxyl Sulfate in the Patients with Lupus Nephritis[J]. 临床医学进展, 2021, 11(01): 235-242. https://doi.org/10.12677/ACM.2021.111034</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39985-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Almaani, S., Meara, A. and Rovin, B.H. (2017) Update on Lupus Nephritis. Clinical Journal of the American Society of Nephrology, 12, 825-835. &lt;br&gt;https://doi.org/10.2215/CJN.05780616</mixed-citation></ref><ref id="hanspub.39985-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sonnenburg, J.L. and Backhed, F. (2016) Diet-Microbiota Interactions as Moderators of Human Metabolism. Nature, 535, 56-64. &lt;br&gt;https://doi.org/10.1038/nature18846</mixed-citation></ref><ref id="hanspub.39985-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Qin, J., Li, R., Raes, J., et al. (2010) A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing. Nature, 464, 59-65. &lt;br&gt;https://doi.org/10.1038/nature08821</mixed-citation></ref><ref id="hanspub.39985-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">李苗, 付冰冰, 等. 系统性红斑狼疮与肠道菌群的相关研究[J]. 新医学, 2016, 47(11): 735-741.</mixed-citation></ref><ref id="hanspub.39985-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chu, S., Mao, X., Guo, H., et al. (2017) Indoxyl Sulfate Potentiates Endothelial Dysfunction via Reciprocal Role for Reactive Oxygen Species and RhoA/ROCK Signaling in 5/6 Nephrectomized Rats. Free Radical Research, 51, 237-252. &lt;br&gt;https://doi.org/10.1080/10715762.2017.1296575</mixed-citation></ref><ref id="hanspub.39985-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hochberg, M.C. (1997) Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis &amp; Rheumatology, 40, 1725. &lt;br&gt;https://doi.org/10.1002/art.1780400928</mixed-citation></ref><ref id="hanspub.39985-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">唐余燕, 贺海东. 肠道微生物群在慢性肾脏病中的作用机制研究进展[J]. 国际泌尿系统杂志, 2019(5): 957-961.</mixed-citation></ref><ref id="hanspub.39985-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hevia, A., Milani, C., Lopez, P., et al. (2014) Intestinal Dysbiosis Associated with Systemic Lupus Erythematosus. MBio, 5, e01548-01514. &lt;br&gt;https://doi.org/10.1128/mBio.01548-14</mixed-citation></ref><ref id="hanspub.39985-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Wang, H.F., Li, X., et al. (2019) Disordered Intestinal Microbes Are Associated with the Activity of Systemic Lupus Erythematosus. Clinical Science, 133, 821-838. &lt;br&gt;https://doi.org/10.1042/CS20180841</mixed-citation></ref><ref id="hanspub.39985-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Azzouz, D., Omarbekova, A., Heguy, A., et al. (2019) Lupus Nephritis Is Linked to Disease-Activity Associated Expansions and Immunity to a Gut Commensal. Annals of the Rheumatic Diseases, 78, 947-956.  
&lt;br&gt;https://doi.org/10.1136/annrheumdis-2018-214856</mixed-citation></ref><ref id="hanspub.39985-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H., Liao, X., Sparks, J.B., et al. (2014) Dynamics of Gut Microbiota in Autoimmune Lupus. Applied and Environmental Microbiology, 80, 7551-7560. &lt;br&gt;https://doi.org/10.1128/AEM.02676-14</mixed-citation></ref><ref id="hanspub.39985-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Petersen, C. and Round, J.L. (2014) Defining Dysbiosis and Its Influence on Host Immunity and Disease. Cellular Microbiology, 16, 1024-1033. &lt;br&gt;https://doi.org/10.1111/cmi.12308</mixed-citation></ref><ref id="hanspub.39985-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">D’amelio, P. and Sassi, F. (2018) Gut Microbiota, Immune System, and Bone. Calcified Tissue International, 102, 415-425. &lt;br&gt;https://doi.org/10.1007/s00223-017-0331-y</mixed-citation></ref><ref id="hanspub.39985-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nowling, T.K. and Gilkeson, G.S. (2011) Mechanisms of Tissue Injury in Lupus Nephritis. Arthritis Research &amp; Therapy, 13, 250. &lt;br&gt;https://doi.org/10.1186/ar3528</mixed-citation></ref><ref id="hanspub.39985-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Schmidt, T., Paust, H.J., Krebs, C.F., et al. (2015) Function of the Th17/Interleukin-17A Immune Response in Murine Lupus Nephritis. Arthritis &amp; Rheumatology, 67, 475-487. &lt;br&gt;https://doi.org/10.1002/art.38955</mixed-citation></ref><ref id="hanspub.39985-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">陈独群, 胡伟新. 狼疮足细胞病: 一种特殊类型的狼疮性肾炎[J]. 肾脏病与透析肾移植杂志, 2017, 26(1): 72-75+94.</mixed-citation></ref><ref id="hanspub.39985-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Vaziri, N.D., Zhao, Y.Y. and Pahl, M.V. (2016) Altered Intestinal Microbial Flora and Impaired Epithelial Barrier Structure and Function in CKD: The Nature, Mechanisms, Consequences and Potential Treatment. Nephrology Dialysis Transplantation, 31, 737-746. &lt;br&gt;https://doi.org/10.1093/ndt/gfv095</mixed-citation></ref><ref id="hanspub.39985-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ellis, R.J., Small, D.M., Vesey, D.A., et al. (2016) Indoxyl Sulphate and Kidney Disease: Causes, Consequences and Interventions. Nephrology (Carlton), 21, 170-177. &lt;br&gt;https://doi.org/10.1111/nep.12580</mixed-citation></ref><ref id="hanspub.39985-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bergstrom, J. and Lindholm, B. (1998) Malnutrition, Cardiac Disease, and Mortality: An Integrated Point of View. American Journal of Kidney Diseases, 32, 834-841. &lt;br&gt;https://doi.org/10.1016/S0272-6386(98)70148-9</mixed-citation></ref><ref id="hanspub.39985-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">唐小芳, 刘虹. 硫酸吲哚酚对心血管毒性作用的研究进展[J]. 中国临床新医学, 2019, 12(7): 697-701.</mixed-citation></ref><ref id="hanspub.39985-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">张发明, 李玥粪. 菌移植治疗炎症性肠病的争议[J]. 协和医学杂志, 2019, 10(3): 211-215.</mixed-citation></ref><ref id="hanspub.39985-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">王珊, 夏耿红, 何彦, 等. 氧化三甲胺分布特征及其与肠道菌群的关联性[J]. 南方医科大学学报, 2016, 36(4): 455-460.</mixed-citation></ref><ref id="hanspub.39985-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Kim, D., Yoo, S.A. and Kim, W.U. (2016) Gut Microbiota in Autoimmunity: Potential for Clinical Applications. Archives of Pharmacal Research, 39, 1565-1576. &lt;br&gt;https://doi.org/10.1007/s12272-016-0796-7</mixed-citation></ref><ref id="hanspub.39985-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Xu, M.Q., Cao, H.L., Wang, W.Q., et al. (2015) Fecal Microbiota Transplantation Broadening Its Application beyond Intestinal Disorders. World Journal of Gastroenterology, 21, 102-111. &lt;br&gt;https://doi.org/10.3748/wjg.v21.i1.102</mixed-citation></ref><ref id="hanspub.39985-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Anwar, S., Bhandari, U., Panda, B.P., et al. (2018) Trigonelline Inhibits Intestinal Microbial Metabolism of Choline and Its Associated Cardiovascular Risk. Journal of Pharmaceutical and Biomedical Analysis, 159, 100-112.  
&lt;br&gt;https://doi.org/10.1016/j.jpba.2018.06.027</mixed-citation></ref><ref id="hanspub.39985-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Wikoff, W.R., Anfora, A.T., Liu, J., et al. (2009) Metabolomics Analysis Reveals Large Effects of Gut Microflora on Mammalian Blood Metabolites. Proceedings of the National Academy of Sciences of the United States of America, 106, 3698-3703. &lt;br&gt;https://doi.org/10.1073/pnas.0812874106</mixed-citation></ref><ref id="hanspub.39985-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Jones, J.D. and Burnett, P.C. (1974) Creatinine Metabolism in Humans with Decreased Renal Function: Creatinine Deficit. Clinical Chemistry, 20, 1204-1212. &lt;br&gt;https://doi.org/10.1093/clinchem/20.9.1204</mixed-citation></ref><ref id="hanspub.39985-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Dou, L., Sallee, M., Cerini, C., et al. (2015) The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid. Journal of the American Society of Nephrology, 26, 876-887. &lt;br&gt;https://doi.org/10.1681/ASN.2013121283</mixed-citation></ref><ref id="hanspub.39985-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Watanabe, H., Miyamoto, Y., Honda, D., et al. (2013) p-Cresyl Sulfate Causes Renal Tubular Cell Damage by Inducing Oxidative Stress by Activation of NADPH Oxidase. Kidney International, 83, 582-592.  
&lt;br&gt;https://doi.org/10.1038/ki.2012.448</mixed-citation></ref><ref id="hanspub.39985-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Meert, N., Eloot, S., Schepers, E., et al. (2011) Comparison of Removal Capacity of Two Consecutive Generations of High-Flux Dialysers during Different Treatment Modalities. Nephrology Dialysis Transplantation, 26, 2624-2630.  
&lt;br&gt;https://doi.org/10.1093/ndt/gfq803</mixed-citation></ref><ref id="hanspub.39985-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Sirich, T.L., Luo, F.J., Plummer, N.S., et al. (2012) Selectively Increasing the Clearance of Protein-Bound Uremic Solutes. Nephrology Dialysis Transplantation, 27, 1574-1579. &lt;br&gt;https://doi.org/10.1093/ndt/gfr691</mixed-citation></ref></ref-list></back></article>